Clicky

Adagene Inc.(ADAG)

Description: Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.


Keywords: Medicine Biopharmaceutical Artificial Intelligence Immunology Health Care Antibodies Immunotherapy Cancer Immunotherapy Antibody Immunotherapies Virotherapy Biontech

Home Page: www.adagene.com

ADAG Technical Analysis

Building C14
Suzhou, 215123
China
Phone: 86 512 8777 3632


Officers

Name Title
Dr. Peter P. Luo Ph.D. Co-Founder, CEO & Chairman
Mr. Man Kin Tam M.B.A. CFO & Director
Dr. Fangyong Du Ph.D. Chief Technology Officer
Dr. Jc Xu M.D., Ph.D. Chief Scientific Officer
Ms. Ami Celeste Knoefler VP of Investor Relations & Corp. Communications
Ms. Ling Zhou Head of HR
Dr. Qinghai Zhao Chief Manufacturing Officer
Ms. Yan Li M.B.A. Sr. VP of Bioinformatics & Information Technology
Ms. Xiaohong She Sr. VP & Head of Clinical Operations
Dr. Guizhong Liu Ph.D. Head of Biology & Pharmacology

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4335
Price-to-Sales TTM: 4.4993
IPO Date: 2021-02-09
Fiscal Year End: December
Full Time Employees: 259
Back to stocks